- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03887793
Quality Improvement Strategies to Increase Human Papillomavirus (HPV) Vaccination in Integrated Healthcare Delivery Systems
February 24, 2020 updated by: University of North Carolina, Chapel Hill
HPV vaccination coverage is at lower levels than the national goal.
This study will evaluate the effectiveness of quality improvement strategies for increasing HPV vaccination coverage among adolescent within the context of large integrated health care delivery systems.
Study Overview
Detailed Description
The University of North Carolina (UNC) will evaluate the impact of a quality improvement (QI) model for increasing HPV vaccination coverage among adolescents in primary care settings.
UNC will partner with the American Cancer Society (ACS) to evaluate the effectiveness of their Vaccinate Adolescents against Cancer (VACs) model for HPV vaccine QI within the context of integrated healthcare delivery systems (IDSs).
The VACs model includes the development of a QI action plan and a QI team.
The QI team is made up of health care providers from participating clinics within the IDSs.
The team then helps implement specific QI activities in participating primary care clinics.
The model also includes vaccination coverage assessments in participating clinics at multiple time points to assess the impact of QI activities.
Specific QI activities that will be offered to participating clinics will be chosen from a menu of options that will include the Center for Disease Control and Prevention's AFIX model and physician-to-physician engagement.
AFIX (Assessment, Feedback, Incentives and eXchange) consists of brief quality improvement consultations that immunization specialists from state health departments deliver to vaccine providers in primary care settings.
Using immunization registry data, the specialist evaluates the clinic's vaccination coverage and delivers education on best practices to improve coverage.
Physician-to-physician (P2P) engagement consists of an in-depth training about how to make strong and effective HPV vaccination recommendations to primary care providers.
The investigators will compare changes in HPV vaccination coverage between the quality improvement arm or wait list control arm.
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New York
-
Albany, New York, United States, 12237
- New York State Department of Health
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53703
- Wisconsin Department of Health Services
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Integrated healthcare delivery systems headquartered in New York State or Wisconsin with at least 4 pediatric or internal medicine practices within the system.
- All clinics within the integrated healthcare delivery system must participate in the state immunization registry.
Exclusion Criteria:
- Integrated healthcare delivery systems headquartered outside of New York State or Wisconsin.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VACs intervention
Integrated healthcare delivery systems randomly assigned to this arm will participate in the Vaccinate Adolescents against Cancers (VACs) model for HPV vaccine QI.
Specific QI activities will be chosen by healthcare system leadership and healthcare providers on the systems' QI teams.
|
The VACs (Vaccinate Adolescents against Cancer) model for HPV vaccine quality improvement is a strategy developed by the American Cancer Society to improve HPV vaccination coverage in large integrated health care delivery systems.
It includes the development of a quality improvement (QI) action plan, the formation of a QI team of health care providers, education for the QI team about HPV-related disease burden and vaccine efficacy, HPV vaccine coverage assessments at several time points that are shared with individual clinics within the health are system, and the adoption of specific QI strategies by participating clinics in the health care system.
|
No Intervention: Wait list control
Integrated healthcare delivery systems randomly assigned to this arm will be placed on a waiting list to receive the intervention after the conclusion of the study period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccination (≥1 dose), 11-12 year olds at 6 months
Time Frame: Six months
|
Coverage change from baseline to 6 months in HPV vaccine initiation (≥1 dose), among 11- to 12- year old patients, as measured by states' immunization information system (IIS) records
|
Six months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV vaccination (≥1 dose), 11-12 year olds at 6 months by state
Time Frame: Six months
|
Coverage change from baseline to 6 months in HPV vaccine initiation (≥1 dose), among 11- to 12- year-old patients, as measured by states' IIS records, stratifying by state (NY or WI)
|
Six months
|
HPV vaccination (completion according to the Advisory Committee on Immunization Practices (ACIP) guidelines), 11-12 year olds at six months
Time Frame: Six months
|
Coverage change from baseline to six months in HPV vaccine completion, among 11- to 12- year-old patients, as measured by states' IIS records
|
Six months
|
HPV vaccination (completion according to the Advisory Committee on Immunization Practices (ACIP) guidelines), 11-12 year olds at six months by state
Time Frame: Six months
|
Coverage change from baseline to six months in HPV vaccine completion, among 11- to 12- year-old patients by state (NY or WI), as measured by states' IIS records
|
Six months
|
HPV vaccination (≥1 dose), 13-17 year olds at six months
Time Frame: Six months
|
Coverage change from baseline to six months in HPV vaccine initiation (≥1 dose), among 13- to 17- year-old patients, as measured by states' IIS records
|
Six months
|
HPV vaccination (completion according to ACIP guidelines), 13-17 year olds at six months
Time Frame: Six months
|
Coverage change from baseline to six months in HPV vaccine completion, among 13- to 17- year-old patients, as measured by states' IIS records
|
Six months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Noel T Brewer, PhD, University of North Carolina
- Principal Investigator: Melissa B Gilkey, PhD, University of North Carolina
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
January 1, 2020
Primary Completion (Anticipated)
July 31, 2020
Study Completion (Anticipated)
July 31, 2020
Study Registration Dates
First Submitted
February 26, 2019
First Submitted That Met QC Criteria
March 21, 2019
First Posted (Actual)
March 25, 2019
Study Record Updates
Last Update Posted (Actual)
February 26, 2020
Last Update Submitted That Met QC Criteria
February 24, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18-0146b
- 1U01IP001073-01 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Human Papillomavirus Infection
-
The AlfredMerck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection | Human PapillomavirusAustralia
-
Merck Sharp & Dohme LLCCompletedHuman Papillomavirus Infection
-
Sanford HealthCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus InfectionBahrain
-
Centre Hospitalier Universitaire de BesanconCompletedHuman Papillomavirus InfectionFrance
-
University Hospital, GenevaCompletedHuman Papillomavirus InfectionSwitzerland
-
University of ConnecticutCompletedHuman Papillomavirus Infection
-
Indiana UniversityMerck Sharp & Dohme LLCUnknownHuman Papillomavirus InfectionUnited States
-
Gen-Probe, IncorporatedCompletedHuman Papillomavirus InfectionUnited States
-
GlaxoSmithKlineCompletedHuman Papillomavirus Infection
Clinical Trials on VACs
-
Soranus ArGe ve Danismanlik Hizmetleri Sanayi Ticaret...Completed